Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Muhlenberg T et al. – Gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT or platelet–derived growth factor receptor A (PDGFRA), and treatment with the tyrosine kinase inhibitor imatinib yields responses in the majority of patients. The results provide preclinical evidence for a disease–specific effect of HDACI in KIT–positive GIST, which could translate into therapeutic activity.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address